Cargando…

Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis

Primary myelofibrosis (PMF) is a Philadelphia-negative (Ph−) myeloproliferative disorder, showing abnormal CD34(+) progenitor cell trafficking, splenomegaly, marrow fibrosis leading to extensive extramedullary haematopoiesis, and abnormal neoangiogenesis in either the bone marrow or the spleen. Mono...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campanelli, Rita, Fois, Gabriela, Catarsi, Paolo, Poletto, Valentina, Villani, Laura, Erba, Benedetta Gaia, Maddaluno, Luigi, Jemos, Basilio, Salmoiraghi, Silvia, Guglielmelli, Paola, Abbonante, Vittorio, Di Buduo, Christian Andrea, Balduini, Alessandra, Iurlo, Alessandra, Barosi, Giovanni, Rosti, Vittorio, Massa, Margherita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4900622/ https://www.ncbi.nlm.nih.gov/pubmed/27281335 http://dx.doi.org/10.1371/journal.pone.0156990

Ejemplares similares

Constitutive STAT5 phosphorylation in CD34(+) cells of patients with primary myelofibrosis: Correlation with driver mutation status and disease severity
por: Abbà, Carlotta, et al.
Publicado: (2019)

JAK2 V617F Genotype Is a Strong Determinant of Blast Transformation in Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2013)

Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2012)

Clinical Relevance of VEGFA (rs3025039) +936 C>T Polymorphism in Primary Myelofibrosis: Susceptibility, Clinical Co-Variates, and Outcomes
por: Villani, Laura, et al.
Publicado: (2021)

New Markers of Disease Progression in Myelofibrosis
por: Campanelli, Rita, et al.
Publicado: (2021)

P989: NEWLY IDENTIFIED ROLES FOR PIEZO1 MECHANOSENSOR IN CONTROLLING NORMAL MEGAKARYOCYTE DEVELOPMENT AND IN PRIMARY MYELOFIBROSIS
por: Abbonante, Vittorio, et al.
Publicado: (2023)

JAK2 Exon 14 Skipping in Patients with Primary Myelofibrosis: A Minor Splice Variant Modulated by the JAK2-V617F Allele Burden
por: Catarsi, Paolo, et al.
Publicado: (2015)

VEGFA rs3025020 Polymorphism Contributes to CALR -Mutation Susceptibility and Is Associated with Low Risk of Deep Vein Thrombosis in Primary Myelofibrosis
por: Villani, Laura, et al.
Publicado: (2021)

VEGFA rs3025039 is associated with phenotype severity of myelofibrosis‐type megakaryocyte dysplasia
por: Barosi, Giovanni, et al.
Publicado: (2023)

P982: MYELOID-DERIVED SUPPRESSOR CELLS: CHARACTERIZATION IN PERIPHERAL BLOOD AND SPLEEN TISSUE OF PATIENTS WITH MYELOFIBROSIS
por: Campanelli, R., et al.
Publicado: (2022)

Elevated plasma EDA fibronectin in primary myelofibrosis is determined by high allele burden of JAK2V617F mutation and strongly predicts splenomegaly progression
por: Malara, Alessandro, et al.
Publicado: (2022)

P1002: PROTEOMIC SCREENING IDENTIFIES MEGAKARYOCYTE DERIVED PF4/CXCL4 AS A CRITICAL DRIVER OF MYELOFIBROSIS
por: Malara, Alessandro, et al.
Publicado: (2023)

iPSC diversity: A key for better use and improved targeting
por: Abbonante, Vittorio, et al.
Publicado: (2021)

EDA fibronectin–TLR4 axis sustains megakaryocyte expansion and inflammation in bone marrow fibrosis
por: Malara, Alessandro, et al.
Publicado: (2019)

Shared and Distinctive Ultrastructural Abnormalities Expressed by Megakaryocytes in Bone Marrow and Spleen From Patients With Myelofibrosis
por: Zingariello, Maria, et al.
Publicado: (2020)

Critical appraisal of the role of ruxolitinib in myeloproliferative neoplasm-associated myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2015)

Impact of the rs1024611 Polymorphism of CCL2 on the Pathophysiology and Outcome of Primary Myelofibrosis
por: Masselli, Elena, et al.
Publicado: (2021)

Myelofibrosis-type megakaryocyte dysplasia (MTMD) as a distinct category of BCR::ABL-negative myeloproliferative neoplasms. Challenges and perspectives
por: Barosi, Giovanni, et al.
Publicado: (2023)

Effect of Interferon-γ on the Basal and the TNFα-Stimulated Secretion of CXCL8 in Thyroid Cancer Cell Lines Bearing Either the RET/PTC Rearrangement Or the BRAF V600e Mutation
por: Rotondi, Mario, et al.
Publicado: (2016)

Megakaryocyte Contribution to Bone Marrow Fibrosis: many Arrows in the Quiver
por: Malara, Alessandro, et al.
Publicado: (2018)

In Vitro Megakaryocyte Differentiation and Proplatelet Formation in Ph-Negative Classical Myeloproliferative Neoplasms: Distinct Patterns in the Different Clinical Phenotypes
por: Balduini, Alessandra, et al.
Publicado: (2011)

Treatment of Myelofibrosis: Old and New Strategies
por: Iurlo, Alessandra, et al.
Publicado: (2017)

miR-494-3p overexpression promotes megakaryocytopoiesis in primary myelofibrosis hematopoietic stem/progenitor cells by targeting SOCS6
por: Rontauroli, Sebastiano, et al.
Publicado: (2017)

Enhanced Expression of Stim, Orai, and TRPC Transcripts and Proteins in Endothelial Progenitor Cells Isolated from Patients with Primary Myelofibrosis
por: Dragoni, Silvia, et al.
Publicado: (2014)

High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis
por: Rosti, Vittorio, et al.
Publicado: (2010)

Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance
por: Breccia, Massimo, et al.
Publicado: (2022)

Role of TGF‐β1/miR‐382‐5p/SOD2 axis in the induction of oxidative stress in CD34+ cells from primary myelofibrosis
por: Rossi, Chiara, et al.
Publicado: (2018)

A new path to platelet production through matrix sensing
por: Abbonante, Vittorio, et al.
Publicado: (2017)

Trend of circulating CD34(+) cells in patients with myelofibrosis: Association with spleen response during ruxolitinib treatment
por: Iurlo, Alessandra, et al.
Publicado: (2022)

Pathophysiological Significance of Store-Operated Calcium Entry in Megakaryocyte Function: Opening New Paths for Understanding the Role of Calcium in Thrombopoiesis
por: Di Buduo, Christian A., et al.
Publicado: (2016)

Inside-to-outside and back to the future of megakaryopoiesis
por: Di Buduo, Christian Andrea, et al.
Publicado: (2023)

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
por: Pietra, D, et al.
Publicado: (2016)

Recombinant Collagen Engineered to Bind to Discoidin Domain Receptor Functions as a Receptor Inhibitor
por: An, Bo, et al.
Publicado: (2016)

Myelofibrosis Treatment Algorithm 2018
por: Tefferi, Ayalew, et al.
Publicado: (2018)

The role of the extracellular matrix in primary myelofibrosis
por: Leiva, O, et al.
Publicado: (2017)

P1000: INCREASED PLASMA LEVELS OF LNCRNAS ARE POTENTIAL PROGNOSTIC BIOMARKERS IN MYELOFIBROSIS
por: Sartini, S., et al.
Publicado: (2022)

Does ruxolitinib really prolong survival in individuals with myelofibrosis? The never-ending story
por: Barosi, Giovanni, et al.
Publicado: (2022)

Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis
por: Fantini, Sebastian, et al.
Publicado: (2021)

Sub-Cellular Localization of Metalloproteinases in Megakaryocytes
por: Malara, Alessandro, et al.
Publicado: (2018)

Incidence of blast phase in myelofibrosis according to anemia severity
por: Mora, Barbara, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_olrc24l39u5r9t1l2ntd9ojlvg